The global antibody drug conjugates market size was valued at USD 11.84 billion in 2024 and is projected to reach from USD 12 ...

Exclusive global license outside of Greater Chinafor MRG007, a novel antibody drug conjugate (ADC) in development for gastrointestinal (GI) ...

In return for these rights, ArriVent will pay Lepu a one-time down payment and near-term milestone payments amounting to ...

IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesion ...

日前，ArriVent BioPharma和乐普生物（Lepu Biopharma）宣布，就针对消化道癌症的潜在“best-in-class”抗体偶联药物（ADC）MRG007达成全球独家许可协议。 MRG007是一款靶点尚未披露的抗体偶联药物，在消化道癌症的临床前模型中表现出强大的抗肿瘤活性，在支持IND的临床前研究中显示出较高的治疗指数。首个IND申请计划于2025年上半年提交，初步临床开发重 ...

The "Antibody Drug Conjugates Market Report 2025-2035" has been added to ResearchAndMarkets.com's offering.World revenue for the Antibody Drug Conjugates Market is set to surpass US$16 billion in 2025 ...

Celltrion targets innovative drug development with new ADC and antibody candidates Celltrion aims for growth by venturing ...

Zai Lab Limited (ZLAB) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation or ODD to ZL-1310, a ...

INCHEON, South Korea, Jan. 15, 2025 /PRNewswire/ -- Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today announced its innovative drug development strategy in the rigorous ...

Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth ...

A recent study has introduced a novel class of antibody-drug conjugates (ADCs) targeting trophoblast cell surface antigen 2 (TROP2), a protein overexpressed in pancreatic ductal adenocarcinoma (PDAC), ...